These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28263463)

  • 1. Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
    Roy-Chowdhury J; Roy-Chowdhury N; Listowsky I; Wolkoff AW
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):140-146. PubMed ID: 28263463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
    Gammal RS; Court MH; Haidar CE; Iwuchukwu OF; Gaur AH; Alvarellos M; Guillemette C; Lennox JL; Whirl-Carrillo M; Brummel SS; Ratain MJ; Klein TE; Schackman BR; Caudle KE; Haas DW;
    Clin Pharmacol Ther; 2016 Apr; 99(4):363-9. PubMed ID: 26417955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Johnson DH; Venuto C; Ritchie MD; Morse GD; Daar ES; McLaren PJ; Haas DW
    Pharmacogenet Genomics; 2014 Apr; 24(4):195-203. PubMed ID: 24557078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
    Li M; Chan WW; Zucker SD
    J Am Heart Assoc; 2020 Oct; 9(19):e016310. PubMed ID: 32930032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
    PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
    Zhang D; Chando TJ; Everett DW; Patten CJ; Dehal SS; Humphreys WG
    Drug Metab Dispos; 2005 Nov; 33(11):1729-39. PubMed ID: 16118329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
    Chang JH; Plise E; Cheong J; Ho Q; Lin M
    Mol Pharm; 2013 Aug; 10(8):3067-75. PubMed ID: 23750830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
    Sane RS; Steinmann GG; Huang Q; Li Y; Podila L; Mease K; Olson S; Taub ME; Stern JO; Nehmiz G; Böcher WO; Asselah T; Tweedie D
    J Pharmacol Exp Ther; 2014 Nov; 351(2):403-12. PubMed ID: 25204339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    Turatti L; Sprinz E; Lazzaretti RK; Kuhmmer R; Agnes G; Silveira JM; Basso RP; Pinheiro CA; Silveira MF; de Almeida S; Ribeiro JP; Mattevi VS
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1015-8. PubMed ID: 22050734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
    Panagopoulos P; Paraskevis D; Katsarolis I; Sypsa V; Detsika M; Protopapas K; Antoniadou A; Papadopoulos A; Petrikkos G; Hatzakis A
    Int J STD AIDS; 2014 Oct; 25(12):860-5. PubMed ID: 24516079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
    Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
    Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
    Culley CL; Kiang TK; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of indinavir-induced hyperbilirubinemia.
    Zucker SD; Qin X; Rouster SD; Yu F; Green RM; Keshavan P; Feinberg J; Sherman KE
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12671-6. PubMed ID: 11606755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.
    Rotger M; Taffe P; Bleiber G; Gunthard HF; Furrer H; Vernazza P; Drechsler H; Bernasconi E; Rickenbach M; Telenti A;
    J Infect Dis; 2005 Oct; 192(8):1381-6. PubMed ID: 16170755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
    HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis.
    Du P; Wang A; Ma Y; Li X
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30962262
    [No Abstract]   [Full Text] [Related]  

  • 18. Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia.
    Dorresteijn MJ; Dekker D; Zwaag J; Heemskerk S; Roelofs HMJ; Smits P; van der Hoeven JG; Wagener FADTG; Pickkers P
    Front Immunol; 2023; 14():1176775. PubMed ID: 37261364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case study 5. Deconvoluting hyperbilirubinemia: differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development.
    Templeton I; Eichenbaum G; Sane R; Zhou J
    Methods Mol Biol; 2014; 1113():471-83. PubMed ID: 24523126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.